Key facts
- This page summarizes Sandy Macrae's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 May 2025, 16:05.
Sandy Macrae - 24 May 2025 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)
- Reporting relationship
- PRESIDENT, CEO AND DIRECTOR, Director
- Issuer ticker
- SGMO
- Reported as of
- 24 May 2025
- Net transaction value
- -$3,544
- SEC form
- 4
- Accepted by SEC
- 28 May 2025, 16:05:05 UTC
- Prior SEC filing
- 24 Apr 2025
- Next SEC filing
- 24 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Prathyusha Duraibabu, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sandy Macrae filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 28 May 2025.
Change
- Previous filing in this sequence was filed on 24 Apr 2025.
- Current net transaction value: -$3,544.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001675687
Primary reporting owner
Macrae Sandy
- Relationship
- PRESIDENT, CEO AND DIRECTOR, Director
- Address
- C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND
- Signature
- /s/ Prathyusha Duraibabu, Attorney-in-Fact
- Signature date
- 28 May 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGMO
transaction
Common Stock
Tax liability
- Transaction value
- $3,544
- Shares
- -7,488
- Change %
- -0.32%
- Price
- $0.4733
- Shares after
- 2,318,410
- Date
- 24 May 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 24, 2025, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 23, 2025 of $0.4733/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
Footnote F2
Includes: (a) 7,259 shares resulting from the May 24, 2025 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 44,241 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 750,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026 and (c) 375,000 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.